Effects of Two GnRH-based Recombinant Vaccine Candidates on Pig Fertility
Resumen
This paper describes for the first time the generation of the K88ab-GnRH hybrid fimbria, the fusion of N. meningitidis P64k protein (P64k-GnRH), and its evaluation as vaccine candidates to control fertility in mammals. Twenty hybrid male pigs were randomly distributed in four groups: placebos and immunized with K88ab-GnRH, P64k-GnRH and a GnRH analogue (GnRHm1), linked to a tetanus toxoid (TT) T-helper epitope (positive control), respectively. The pigs were immunized at 9-10 weeks of age, using a two-dose scheme, and were sacrificed sixteen weeks later. K88ab-GnRH, P64k-GnRH, and GnRHm1-TT induced higher, similar, and lower testosterone levels in the serum, compared to the placebo, respectively. In the K88ab-GnRH group, the pigs underwent a reduction in testicle size and weight (P < 0.01), and a reduction in the weight of epididymes compared to the placebo; none of them was able to ejaculate. In the P64k-GnRH group, the pigs had a reduction in testicle weight (P < 0.05), and only one of them was able to ejaculate. The testicles of the pigs immunized with K88ab-GnRH and P64k-GnRH showed structural and functional damage; spermatogenesis was also affected. The accessory sexual glands of the P64k-GnRH group were normal, in contrast to K88ab-GnRH, where interstitial fibrosis was observed. The damage caused by K88ab-GnRH and P64k-GnRH in the target organs evaluated were in all cases lower than the affectations caused by the GnRHm1-TT peptide.
Descargas
Los autores de los artículos publicados en RPA retienen los derechos de autor de su trabajo, de marca y patente, y también sobre cualquier proceso o procedimiento descrito en el artículo, así como a compartir, copiar, distribuir, ejecutar y comunicar públicamente el artículo publicado en la RPA o cualquier parte de aquel siempre que indiquen la fuente de publicación (autores del trabajo, revista, volumen, número y fecha), pero están de acuerdo en que la revista publique los trabajos bajo una licencia Creative Commons.
Licencia Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)